Participation in any other study in which receipt of an investigational study drug occurred within  days or  half-lives (whichever is longer) prior to first dose
Within two weeks ( weeks for biologics) of first administration of BI , or if the half-life of the previous product is known, within  times the half-life, whichever is longer.
Treatment with any investigational drug or therapy within  weeks of study treatment, or  half-lives, whichever is longer, before the first dose of study treatment, or ongoing clinically significant adverse events (AEs) from previous treatment.
Antitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy, retinoid therapy, or investigational agent) within  days or  half lives (whichever is longer) of day .
Received investigational agents within  days or  half-lives prior to the first study dosing day, whichever is longer
Participation in any interventional study within  weeks or  half lives (whichever is longer) of Cycle  Day .
Previous chemotherapy and hormone therapy (excluding physiologic replacement) must be completed at least  weeks or  half-lives, whichever is longer, prior to administration of TAK-
Participation in any other clinical study with investigational drug received within  days or  half lives (whichever is longer) before first dose
Any investigational treatment within  days or  half-lives, whichever is longer, of Day  of treatment
Receipt of an investigational study drug for any indication within  days or  half-lives (whichever is longer) prior to day  of protocol therapy
Subject has received anti-myeloma treatment within  weeks or  pharmacokinetic (PK) half-lives (t/) of the treatment, whichever is longer, before the date of start of treatment.
Participation in any interventional study within  weeks of randomization or  half-lives of the prior treatment agent (whichever is longer).
? days or  half-lives (whichever is longer) before the first dose for all other investigational study drugs or devices.
Treatment with experimental therapy within  terminal half-lives (t/) or  weeks prior to enrollment, whichever is longer.
Other IPs w/in  wks or  half-lives (whichever is longer) prior to study drug
Received IPs within  days or  half-lives of the first study dosing day, whichever is longer.
Treatment with an investigational drug within  days or  half-lives (whichever is longer) preceding the first dose of study medication
Treatment with an EGFR TKI within  days or  half-lives of the first dose of study treatment, whichever is longer
Chemotherapy: within  days or  half-lives (whichever is longer) from enrolment
Subject has received an investigational drug in the  day period before the first dose of study drug (or within  half-lives if longer) or is currently participating in another interventional clinical trial.
Has received prior anticancer therapy, monoclonal antibody, chemotherapy, or an investigational agent or device within  weeks or  half-lives (whichever is longer) before first dose of study treatment or not recovered (i.e., must be ? Grade  or at Baseline) from AEs due to previously administered agents.
Any other investigational agents within  weeks or =<  x half-lives (whichever is longer) before start of study therapy
Use of other investigational drugs (drugs not marked for any indication) within  days or at least  half-lives (whichever is longer) before study drug administration
Subjects who participated in any other study in which receipt of an investigational study drug or device occurred within  days or  half-lives (whichever is longer) prior to first dose.
Antitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy, or investigational agent) within  days (Group  subjects) or  half-lives (whichever is longer: for Group  subjects) of day .
Monoclonal antibody treatment and agents with known prolonged half-lives: <  halflives have elapsed or ?  days prior to screening, whichever is longer.
Subject has received therapy with a known moderate to potent CYPA inhibitor within  days or  half-lives of first dose of study treatment (whichever is longer).
Receipt of an investigational study drug for any indication within  days or  half-lives (whichever is longer) prior to day  of protocol therapy
Subject has received investigational therapy, with the exception of oncology drug trials, within  days or  half-lives, whichever is longer, prior to screening.
Participant must not have been treated with any investigational drug within  days or  half-lives of the drug (whichever is longer) prior to the first dose of study drug, or is currently enrolled in another clinical study.
have received any other investigational drug within  days (or  half-lives, if longer) prior to the start of study screening.
Treatment with any concurrent cytotoxic chemotherapy or investigational drug(s) within  weeks or  half lives of the drug (whichever is longer) before Day  and/or during study participation
Patients may not be receiving any other investigational agents during protocol therapy, or up to  days or  half-lives (whichever is longer) prior to beginning protocol therapy; there should be a least a -week interval between last dose of endocrine therapy and protocol therapy
Receipt of any systemic anti-cancer agent, including investigational anti-cancer products, within  days prior to study drug administration or  half-lives, whichever is longer.
Use of any potent cytochrome P A inhibitors or inducers within  days or  half-lives (whichever is longer) before the first dose of study drug.
Treatment with any investigational drug within  days or  half-lives of the investigational drug, whichever is longer
Treatment with anticancer therapy, including investigational therapy, or investigational procedures within  days or  x the half?life (whichever is longer) prior to the first dose of study drug. For prior biological therapies, eg, monoclonal antibodies with a half?life longer than  days, the interval must be at least  days prior to the first dose of study drug.
Use of known substrates or inhibitors of breast cancer resistance protein (BCRP) transporters within  days or  x the half?life (whichever is longer) prior to the first dose of study drug.
Treatment with any investigational products, radiation therapy, surgery, tumor embolization, chemotherapy or immunotherapy within  days before the first dose of the study drug; for biologic or hormonal therapy treatment within  days or five half-lives of a drug (whichever is longer) before the first dose of study drug
Any anti-cancer therapy (eg, chemotherapy, biologics, radiotherapy, or hormonal treatment) within  weeks or at least  half-lives (whichever is longer) of study drug administration
Participation in another interventional study requiring investigational treatment intake within  weeks or at least  half-lives (whichever is longer) prior to first dose of S (participation in non-interventional registries or epidemiological studies is allowed).
Received investigational products within  days or  half-lives of the first study dosing day, whichever is longer
Any prior (neo) adjuvant anti-cancer therapy or prior chemotherapy for metastatic disease must be stopped at least  half-lives or  days, whichever is longer, before study inclusion.
Oral targeted therapy within five days or five half-lives, whichever is longer, prior to initiating protocol therapy treatment
Prior chemotherapy must have been completed at least  weeks or at least  half-lives (whichever is longer) before study drug administration, and all adverse events have either returned to baseline or stabilized; for EGFR and ALK tyrosine kinase inhibitor (TKI)  half-lives wash out is required
Treatment with any investigational medicinal product (IMP) within  weeks prior to initiation of st infusion of study drug, or treatment with a drug that has not received regulatory approval for any indication within  weeks or a minimum of  half-lives, whichever is longer, of the st infusion of study drug.
Medications known to cause QTc interval prolongation (within  days OR five half-lives prior to Study Day , whichever is longer).
Participation in a clinical study within  days or  half-lives of the drug, whichever is longer.
Prior therapy with investigational drugs within  days or at least  half-lives (whichever is longer) before study administration
Applicable to Cohorts - and Cohort  only: Previous anti-cancer and investigational agents within  weeks or ?  x half-life of the agent (whichever is longer) before first dose
Has participated in another interventional clinical study and received investigational drug within  days or  half-lives, whichever is longer, prior to the planned first dose of tazemetostat
Have used any approved TKIs or investigational agents within  weeks or  half-lives of the agent, whichever is longer, prior to receiving study drug
Aspirin within  days, or  half-lives, whichever is longer
An antiplatelet/anticoagulant drug or a herbal supplement that affects platelet function within  days, or  half-lives, whichever is longer
Use of any investigational drug, other than eltrombopag or romiplostim, ?  days or  half-lives of the investigational drug (whichever is longer) prior to the first dose of RTX-
Any investigational drug within  days or five half-lives (whichever is longer) preceding the first dose of SB-
Administration of any non-oncologic investigational drug within  days or  half-lives (whichever is longer) prior to the first dose of pazopanib
Use of an investigational drug outside this study within  days or  half-lives, whichever is longer, preceding the first dose of study medication.
Patients who have discontinued any of these medications must have a wash-out period of at least  days or at least  half-lives of the drug (whichever is longer) prior to the first dose of dinaciclib
Unable or unwilling to discontinue use of prohibited medications for at least  days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study; administration of any non-oncologic investigational drug within  days or  half-lives whichever is longer prior to receiving the first dose of study treatment
Subject has received investigational therapy within  days or  half lives, whichever is longer, prior to screening
Received an investigational agent within  half-lives or  days, whichever is longer, prior to receiving the first dose of study drug
Chemotherapy within  days ( weeks for nitrosoureas) or at least  half-lives (whichever is longer) prior to study treatment.
Treatment with any local or systemic anti-neoplastic therapy or investigational anticancer agent within  days or  half-lives, whichever is longer, up to a maximum wash-out period of  days prior to the initiation of study drug administration
Chemotherapy, biologic therapy, immunotherapy, radiotherapy or investigational agents within  half-lives or within  weeks (whichever is longer) prior to administration of the first dose of study drug on Day  or have not recovered from the side effects of such therapy;
Use of an investigational drug within  days or five half-lives (whichever is longer) preceding the first dose of study drug.
Discontinuation of all therapy (including radiotherapy, chemotherapy, tyrosine-kinase inhibitors [TKIs], immunotherapy or investigational therapy) for the treatment of cancer as follows:\r\n* At least  week or  half-lives (whichever is longer) from the last dose of prior anti-cancer therapy and the initiation of study therapy\r\n* Exceptions or modifications to the above are as follows:\r\n** Medications that are typically part of a maintenance therapy for ALL, such as glucocorticoids or mercaptopurine, may be administered up to  days prior to the first dose, except vinca alkaloids which must be discontinued at least  days prior to the start of study treatment; TKIs are not permitted to be continued at screening (e.g. Gleevec)\r\n* Intrathecal (IT) chemotherapy may be dosed up to  days prior to first dose of pembrolizumab (cytarabine [Ara-C] recommended)\r\n* For biologics (e.g. monoclonal antibodies), washout period of  month beyond the recommended dosing interval and at least  weeks or  half-lives (whichever is longer) since the last dose
Tyrosine kinase inhibitors within  days or  half-lives, whichever is longer, before the first dose of study treatment.
Use of an investigational drug within  days or  half-lives, whichever is longer, preceding the first dose of study drug
DOSE ESCALATION COHORT: Participation in any other study in which receipt of an investigational study drug occurred within  days or  half-lives (whichever is longer) before first dose
DOSE EXPANSION COHORT: Participation in any other study in which receipt of an investigational study drug occurred within  days or  half-lives (whichever is longer) before first dose
No prior treatment with a small molecule kinase inhibitor or a hormonal therapy within  days or  half-lives (whichever is longer)
Chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy\n             will not be allowed within either  days, or  half lives (whichever is longer)\n             prior to study drug administration.
At least  days or  half-lives, whichever is longer, must have elapsed since prior treatment with a monoclonal antibody
Has participated in another interventional clinical study and received investigational drug within  days or  half-lives, whichever is longer, prior to the planned first dose of tazemetostat
Use of any investigational drug within  days or  half-lives, whichever is longer, preceding enrollment
Subjects who participated in any other study in which receipt of an investigational study drug or device occurred within  weeks or  half-lives (whichever is longer) prior to first dose.
Unable or unwilling to discontinue use of prohibited medications for at least  days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study
Has received investigational agents within  days or  half-lives (whichever is longer) of Study Day 
Administration of any investigational drug within  days or  half-lives, whichever is longer, preceding the first dose of study treatment
Administration of any non-oncologic investigational drug within  days or  half-lives (whichever is longer) prior to the first dose of pazopanib
Use of any investigational agents within  days or  half-lives (whichever is longer) of initiating study treatment
Participation in a therapeutic clinical study within  weeks for biological treatments, and within  weeks or  half-lives, whichever is longer, for small molecule agents, before study drug treatment
Any investigational agents within  days or  half-lives (whichever is longer) of initiating study treatment
Has received investigational agents within  days or  half-lives (whichever is longer) of Study Day 
Use or expected use during the study of any prohibited medications, including potent cytochrome P A inhibitors or inducers within  days or  half lives (whichever is longer) before the first dose of study drug.
Investigational drug;  days or five half-lives, whichever is longer, from last dose
Tyrosine kinase inhibitor (TKI) therapy within  weeks or at least  half-lives (whichever is longer) prior to planned start of study treatment.
Use of other investigational drugs within  weeks or  half-lives (whichever is longer) prior to study treatment.
Participation in any other study in which receipt of an investigational study drug or device occurred within  weeks or  half-lives (whichever is longer) before first dose.
Anti-tumor therapy (chemotherapy, chemoradiation, radiation, molecular targeted therapy) within  days or  half-lives whichever is longer, of study drug dosing ( weeks for nitrosoureas, mitomycin C, or molecular agents with t/ >  days);  half-lives of any investigational drug; concurrent use of goserelin for pre-/peri-menopausal breast cancer and exemestane or fulvestrant per the protocol are permitted
Have received oral anti-cancer therapy with oral tyrosine kinase inhibitors within  days or  half-lives, whichever is longer.
Any investigational drug therapy less than  days or  half-lives (whichever is longer) prior to first dose of study treatment
Patients that received glucocorticoid replacement therapy post-operatively must have discontinued such therapy for at least one week, or  half-lives, whichever is longer, prior to screening.
Use of other investigational drugs at the time of enrollment, or within  days or  half lives at the time of enrollment, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations.
Has received prior anti-cancer therapy, monoclonal antibody, chemotherapy, or an investigational agent or device within  weeks or  half-lives (whichever is longer) before first dose of trial drug or not recovered (? Grade  or at baseline) from AEs due to previously administered agents (Parts A and B)
Any anti-cancer therapy (e.g., chemotherapy, biologics, radiotherapy, or hormonal treatment) within  weeks or at least  half-lives (whichever is longer) of study drug administration
Subject has received an investigational drug in the  day period before the first dose of study drug (or within  half-lives if longer) or is currently participating in another interventional clinical trial.
Use of any investigational drugs within  days or  half-lives, whichever is longer, prior to screening, and
Participation in any other clinical studies involving investigational drug(s) within  days or within  half-lives of drug levels in blood (whichever is longer) prior to the first dose of bosutinib.
Administration of an investigational drug within  days or  half-lives, whichever is longer, preceding the first dose of study treatment
Treatment with any known non-marketed drug substance or experimental therapy within  terminal half-lives or  weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical study
Administration of an investigational drug within  days or  half-lives, whichever is longer, preceding the first dose of study treatment.
Biologic (anti-neoplastic agent): At least  days or  half-lives (whichever is longer) since the completion of therapy with a biologic agent
Any prior (neo) adjuvant anti-cancer therapy must be stopped at least  half-lives or  days, whichever is longer, before randomization
Unable or unwilling to discontinue use of prohibited medications for at least  days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study
Administration of any non-oncologic investigational drug within  days or  half lives whichever is longer prior to receiving the first
Anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks or five times of the drug half life, whichever is longer, of the first dose of ARQ 
Treatment with experimental non-Food and Drug Administration (FDA) approved therapy within  terminal half-lives or  weeks prior to enrollment, whichever is longer
Antineoplastic therapy with biological agents within  weeks before day  or within  drug half-lives (t) prior to first dose, whichever time period is longer
Treatment with another investigational drug during the study or within  weeks before day  or within  drug half-live (t) prior to first dose, whichever time period is longer
Unable or unwilling to discontinue use of prohibited medications listed for at least  days or five half-lives of a drug (whichever is longer) prior to registration and for the duration of the study
Treatment with any of the following anti-cancer or non-oncologic investigational therapies: \r\n* Radiation therapy, surgery or tumor embolization within  days prior to registration\r\n* Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within  days or . half-lives of a drug (whichever is longer) prior to registration\r\n* Non-oncologic investigational products within  days or  half-lives prior to registration, whichever is longer
Treatment with any known non-marketed drug substance or experimental therapy within  terminal half-lives or  weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical study
Patients may have received prior VHL-related systemic therapy, provided not within  days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib
Unable or unwilling to discontinue use of prohibited medications list for at least  days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study
Treatment with any known non-marketed drug substance or experimental therapy within  terminal half-lives (calculated by multiplying the reported terminal half-life by ) or  weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical study
Administration of any non-oncologic investigational drug within  days or  half-lives whichever is longer prior to receiving the first dose of study treatment
Unable or unwilling to discontinue use of prohibited fruit (or its juices) and prohibited medications for at least  days or  half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study
Treatment with an investigational drug within  days or  half-lives (whichever is longer) preceding the first dose of study medication
The participant has received an experimental treatment in a clinical trial within the last  days or  half-lives, whichever is longer.
For patients previously treated with chemotherapy, targeted therapy, immunotherapy, or treatment with an investigational anticancer agent, discontinuation must have occurred ? weeks, or after at least  half-lives, whichever is longer, prior to study drug administration. For enzalutamide and apalutamide, the washout period will be at least  weeks prior to start of study drug with no evidence of an anti-androgen withdrawal response (i.e., no decline in serum PSA).
Current treatment with an investigational study drug or immunological-based agent for any reason, or receipt of anticancer medication within  days or  half-lives (whichever is longer) before first dose.
Radiation therapy within  days or  half-lives prior to CD, whichever is longer
Investigational drug use within  days or  half-lives, whichever is longer, prior to CD
Subject has received investigational therapy within  days or  half-lives, whichever is longer, prior to the first dose of study drug.
Non-cytotoxic small molecule therapeutics: ? half-lives or ? weeks (whichever is longer)
Use of other investigational drugs at the time of enrollment, or within  half-lives of enrollment, or until the expected PD effect has returned to baseline, whichever is longer; or even longer if required by local regulations. Concomitant investigational treatment, including treatment in the context of a clinical trial with marketed drugs (off-label) may be acceptable but requires approval by the sponsor on the case by case basis.
Investigational drug use within  days (or  half-lives, whichever is longer) of the first dose of PLX.
Strong CYPA inhibitors or inducers as well as inhibitors of breast cancer resistance protein (BCRP) within  days or  drug half-lives, whichever is longer, before start of study drug.
Received an investigational study drug within  days or  half-lives (whichever is longer) prior to receiving the first dose of study drug.
Received any approved anticancer medications within  days or  half-lives (whichever is longer) prior to receiving their first dose of study drug EXCEPT steroids at ?  mg prednisone daily (or equivalent).
Subjects who had received investigational drug treatment, including BAY and docetaxel, outside of this study within  weeks before the first dose of study drug, or for small molecules within the  half-lives of the agent before the first dose of study drug, whichever is longer
Participated in any interventional study within  weeks of randomization or  half lives (whichever is longer).
Unable or unwilling to discontinue use of prohibited medications for at least  days or five half-lives of a drug, whichever is longer, prior to the first dose of study drug and for the duration of the study treatment.
Administration of any non-oncologic investigational drug within  days or five half-lives (whichever is longer) prior to the protocol-mandated -week drug holiday.
Strong CYPA inhibitors or inducers within  days or  drug half-lives of the agent, whichever is longer, of study drug initiation or the need to continue these drugs during this study.
Within two weeks ( weeks for biologics or  half-lives, whichever is longer) of first administration of BI ; or
Patients who have received other investigational drugs within  weeks or  half-lives (whichever is longer) prior to study enrollment
Prior therapy with any biologic chemotherapeutic or investigational drug within  half-lives or  weeks, whichever is longer prior to the first dose of TKM .
At least  days or  half-lives, whichever is longer, must have elapsed since prior treatment with a monoclonal antibody
Washout from prior chemotherapy of at least  weeks or  elimination half-life, whichever is longer, prior to CD
Any investigational or experimental therapy or procedure or participation in any interventional trial within  weeks or  half-lives (whichever is longer) prior to start of study treatment
Use of other investigational drugs at the time of enrollment, or within  days or  half-lives of enrollment, whichever is longer
Subject has participated in any interventional clinical study or has been treated with any investigational drugs within  days or  half-lives, whichever is longer, prior to the initiation of screening.
Patients who have taken part in an experimental drug study within  weeks or  half-lives (whichever is longer) of initiating treatment with LDE
Participated in a therapeutic clinical study within  weeks ( weeks or  half-lives, whichever is longer, for small-molecule targeted agents) before study drug treatment, or current participation in other therapeutic investigational procedures.
Received investigational agents within  days or  half-lives of the first study dosing day, whichever is longer.
Treatment with an investigational drug within  days or  half lives, whichever is longer, preceding the first dose of study medication.
Administration of an investigational study treatment within  days or  half-lives, whichever is longer, preceding the first dose of study treatment(s) in this study
Use of any investigational drug within  days or  half-lives, whichever is longer, preceding enrollment; for the purposes of this study, bevacizumab will not be considered investigational therapy
Treatment with any known non-marketed drug substance or experimental therapy within  terminal half lives or  Weeks prior to first study treatment dose, whichever is longer, or participation in any other interventional clinical study.
Unable or unwilling to discontinue use of prohibited medications for at least  days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of study treatment.
Subjects who have received any anti-cancer therapy, including radiotherapy, cytotoxic, hormonal, biological (including humanized antibodies) and targeted agents within  days, or five half-lives of the drug (whichever is longer) prior to randomization.
Use of any investigational agents within  days or  half-lives (whichever is longer) of treatment
Used an investigational drug within  days or  half-lives, whichever is longer, preceding the first dose of study medication.
Used an investigational drug within  days or  half-lives, whichever is longer, preceding the first dose of protocol treatment;
Treatment with any investigational drug within  weeks or  half lives (whichever is longer) of the first dose of elotuzumab.
Have stopped previous anticancer therapy for at least  weeks or  half-lives (whichever is longer) if the immediate prior regimen included only chemotherapy; or  weeks or  half-lives (whichever is longer) from any therapy with therapeutic biologics and from any type of investigational therapy.
Treatment within  days or five half lives prior to enrollment whichever is longer with any type of systemic anticancer-therapy or any investigational drug
Treatment within  days or five half lives prior to enrollment with any type of systemic anticancer-therapy or any investigational drug, whichever is longer.
Patients who have taken any medication classified as a strong CYPA inducer within one week of study day  or  half-lives (whichever is longer) or use of a strong or moderate CYPA inhibitor within one week of study day  or  half-lives (whichever is longer)
Patient must not have been dosed with test drug or blinded study drug in another investigational study within  days or  half-lives of the biologic activity of the test drug, whichever is longer, before the time of first study dose
Treatment with an investigational drug within  days or  half-lives (whichever is longer) preceding the first dose of study medication
Patients who have taken part in an experimental drug study within  weeks or  half-lives, whichever is longer, of initiating treatment with LDE
Treatment with any non-Food and Drug Administration (FDA) approved agent within  weeks (or  half-lives of the investigational drug, whichever is longer) of study enrollment
German centers only: Treatment with any known non-marketed drug substance or experimental therapy within  terminal half lives or  weeks prior to enrollment, whichever is longer, or participation in any other interventional clinical study.
Patient must not have been dosed with test drug or blinded study drug in another investigational study within  days or  half-lives of the biologic activity of the test drug, whichever is longer, before the time of first study dose
Biologic or other approved molecular targeted small molecule inhibitors should be washed out  week or  half-lives (whichever is longer) before apheresis and must be completed at least  week or  half-lives (whichever is longer) prior to pre-infusion lymphodepletive chemotherapy.
Use of any investigational drug within  days or  half-lives, whichever is longer, preceding enrollment
Patient must not be unable or unwilling to discontinue use of prohibited medications for at least  days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study
Chemotherapy or targeted therapy within  days or  half-lives (whichever is longer) prior to the start of study treatment
Prior anti-cancer therapy within  days or  times the half-life whichever is longer
Received IPs within  days or  half-lives of the first study dosing day, whichever is longer